Track Mayne Pharma Group Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Mayne Pharma Group Limited MYX.AX · Stock Open Mayne Pharma Group Limited in new tab

2.69 AUD
P/E
8.87
EPS
0.31
P/B
0.57
ROE
8.20
Beta
1.03
Target Price
4.50 AUD
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
P/E8.87
EPS0.31
Book Value4.81
Price to Book0.57
Debt/Equity11.05
% Insiders22.612%
Growth
Revenue Growth-0.12%
Estimates
Forward P/E-8.18
Forward EPS-0.34
Target Mean Price4.50

DCF valuation

Model fair value for Mayne Pharma Group Limited (MYX.AX)
Result
Sign in to run the valuation for MYX.AX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 4.50 AUD (low 3.75, high 5.25)
Low 3.75
Mean 4.50
High 5.25
Price 2.69
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Mayne Pharma Group Limited Logo Mayne Pharma Group Limited Analysis (MYX.AX)

Australia Health Care Official Website Stock

Is Mayne Pharma Group Limited a good investment? Mayne Pharma Group Limited (MYX.AX) is currently trading at 2.69 AUD. Market analysts have a consensus price target of 4.50 AUD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 8.87. This relatively low multiple may signal that Mayne Pharma Group Limited is undervalued compared to historical market norms.

Earnings Schedule: Mayne Pharma Group Limited is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is -0.34.

Investor FAQ

Does Mayne Pharma Group Limited pay a dividend?

No, it does not currently pay a dividend.

What asset class is Mayne Pharma Group Limited?

Mayne Pharma Group Limited is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of 0.31.

Company Profile

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Exchange Ticker
PNK (United States) MAYNF
FRA (Germany) HG6.F
ASX (Australia) MYX.AX
Trades
Dividend History paid per year (AUD)
Historical Dividends
Year Total Dividends
▸2023
0.03 AUD
Jan. 27, 2023 0.0272
▸2011
0.00 AUD
March 2, 2011 0.0005
▸2010
0.00 AUD
Oct. 24, 2010 0.0010
Stock Splits
Split Date Split Ratio to 1
Oct. 8, 2012 1.29
Feb. 12, 2015 1.03
June 30, 2016 1.05
Jan. 18, 2023 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion